| |
All
|
LGG
|
HGG
|
Non-glioma tumors
|
NNL
|
|---|
|
N
|
90
|
27
|
30
|
10
|
23
|
|
Age range (mean ± SD, y)
|
3–78 (40.0 ± 14.0)
|
3–67 (34.0 ± 13.9)
|
14–61 (43.5 ± 12.6)
|
21–69 (42.0 ± 15.3)
|
22–78 (41.6 ± 14.0)
|
|
Sex (M: F)
|
3:2
|
19:8
|
16:14
|
3:7
|
16:7
|
|
Final diagnose
| |
WHO
|
Grade I
|
WHO
|
Grade III
| |
|
PA
|
4
|
AA
|
4
|
|
WHO
|
Grade II
|
AO
|
3
|
|
DA
|
1
|
AE
|
1
|
|
GA
|
1
|
Astrocytoma 11
|
|
OD
|
4
|
WHO
|
Grade IV
|
|
OA
|
1
|
GBM
|
11
|
|
Astrocytoma 16
| | |
- LGG low-grade glioma, HGG high-grade glioma, NNL non-neoplastic lesions, PA pilocytic astrocytoma, DA diffuse astrocytoma, GA gemistocytic astrocytoma, OD oligodendroglioma, OA oligoastrocytoma, AA anaplastic astrocytoma, AO anaplastic oligodendroglioma, AE anaplastic ependymoma, GBM glioblastoma
